• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

碳青霉烯类耐药肠杆菌科血流感染的死亡因素和抗生素选择:具有同时存在的 NDM-1 和 OXA-48 的高流行地区的相关见解。

Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.

机构信息

Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.

Department of Pharmacy Practice, College of Pharmacy, Rangsit University, Pathum Thani, Thailand.

出版信息

Clin Transl Sci. 2024 Jun;17(6):e13855. doi: 10.1111/cts.13855.

DOI:10.1111/cts.13855
PMID:38853376
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11163016/
Abstract

Bloodstream infections (BSI) caused by carbapenem-resistant Enterobacterales (CRE) are associated with a high mortality rate. This study aimed to investigate factors associated with 14-day mortality and identify a potential treatment option. A retrospective cohort study was conducted on patients with CRE-BSI in Thailand from 2015 to 2020. The multivariate Cox proportional-hazards model was employed to identify factors influencing 14-day mortality. Out of 134 diagnosed cases of CRE-BSI, the all-cause 14-day mortality rate was 35.1%. The most prevalent organism isolated was Klebsiella pneumoniae (85.8%), followed by Escherichia coli (11.9%). Among the 60 isolates tested for carbapenemase genes, the majority exhibited co-occurring bla and bla (51.7%), followed by bla (31.7%) and bla (15.0%). In the multivariate analysis, neutropenia (adjusted hazard ratio [aHR] 2.55; 95% confidence interval [95%CI] 1.28-5.06; p = 0.008), sepsis/septic shock (aHR 3.02; 95%CI 1.33-6.86; p = 0.008), and previous metronidazole exposures (aHR 3.58; 95%CI 1.89-6.71; p < 0.001) were identified as independent factors for 14-day mortality. The fosfomycin-based regimen was found to be protective (aHR 0.37; 95%CI 0.15-0.92; p = 0.032). In patients with CRE-BSI, particularly in regions with a high occurrence of co-occurring bla and bla, neutropenia, sepsis/septic shock, and previous metronidazole exposures emerged as independent risk factors for mortality. Moreover, the fosfomycin-based regimen showed an improvement in the survival rate.

摘要

血流感染(BSI)由碳青霉烯类耐药肠杆菌科(CRE)引起,死亡率高。本研究旨在探讨与 14 天死亡率相关的因素,并确定潜在的治疗选择。对 2015 年至 2020 年泰国 CRE-BSI 患者进行了回顾性队列研究。采用多变量 Cox 比例风险模型确定影响 14 天死亡率的因素。在确诊的 134 例 CRE-BSI 患者中,全因 14 天死亡率为 35.1%。最常见的分离菌为肺炎克雷伯菌(85.8%),其次是大肠埃希菌(11.9%)。在对 60 株碳青霉烯酶基因进行检测的菌株中,大多数同时存在 bla 和 bla(51.7%),其次是 bla(31.7%)和 bla(15.0%)。多变量分析显示,中性粒细胞减少症(调整后的危险比[aHR] 2.55;95%置信区间[95%CI] 1.28-5.06;p=0.008)、败血症/感染性休克(aHR 3.02;95%CI 1.33-6.86;p=0.008)和先前甲硝唑暴露(aHR 3.58;95%CI 1.89-6.71;p<0.001)是 14 天死亡率的独立因素。磷霉素方案被发现具有保护作用(aHR 0.37;95%CI 0.15-0.92;p=0.032)。在 CRE-BSI 患者中,特别是在同时存在 bla 和 bla 的高发地区,中性粒细胞减少症、败血症/感染性休克和先前甲硝唑暴露是死亡率的独立危险因素。此外,基于磷霉素的方案显示出生存率的提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54d4/11163016/1ffe7ec0928a/CTS-17-e13855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54d4/11163016/1ffe7ec0928a/CTS-17-e13855-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54d4/11163016/1ffe7ec0928a/CTS-17-e13855-g001.jpg

相似文献

1
Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.碳青霉烯类耐药肠杆菌科血流感染的死亡因素和抗生素选择:具有同时存在的 NDM-1 和 OXA-48 的高流行地区的相关见解。
Clin Transl Sci. 2024 Jun;17(6):e13855. doi: 10.1111/cts.13855.
2
Carbapenem-resistant Enterobacterales among patients with bloodstream infections in South Africa: Consolidated surveillance data, 2015-2021.南非血流感染患者中耐碳青霉烯类肠杆菌科细菌:2015 - 2021年综合监测数据
PLoS One. 2025 Jul 2;20(7):e0324262. doi: 10.1371/journal.pone.0324262. eCollection 2025.
3
A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant versus .耐碳青霉烯类所致菌血症血液病患者临床结局的比较分析 与……相对比 (原文此处不完整)
Front Cell Infect Microbiol. 2025 Jun 17;15:1600746. doi: 10.3389/fcimb.2025.1600746. eCollection 2025.
4
Improved diagnostic stewardship in carbapenem-resistant gene detection helps in early initiation of targeted therapy.改善耐碳青霉烯类基因检测中的诊断管理有助于早期启动靶向治疗。
J Med Microbiol. 2025 Jun;74(6). doi: 10.1099/jmm.0.002029.
5
Clinical outcomes of phenotype-guided treatment in group D carbapenemase-producing bacteremia.产D组碳青霉烯酶菌血症中表型导向治疗的临床结局
Microbiol Spectr. 2025 Jul;13(7):e0027325. doi: 10.1128/spectrum.00273-25. Epub 2025 May 27.
6
Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital.碳青霉烯类耐药肠杆菌科细菌血流感染患儿的临床结局及治疗方式的影响:一项来自三级大学医院的回顾性队列研究
J Antimicrob Chemother. 2025 Jan 3;80(1):147-153. doi: 10.1093/jac/dkae387.
7
Molecular epidemiology and clinical characteristics of carbapenem-resistant bloodstream and pneumonia isolates.耐碳青霉烯类血流感染和肺炎分离株的分子流行病学及临床特征
Microbiol Spectr. 2025 Aug 5;13(8):e0063125. doi: 10.1128/spectrum.00631-25. Epub 2025 Jul 9.
8
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study).头孢他啶/阿维巴坦治疗肿瘤血液科中性粒细胞减少患者产碳青霉烯酶肠杆菌科细菌所致血流感染(TARZAN研究)
J Antimicrob Chemother. 2025 Jun 3;80(6):1673-1681. doi: 10.1093/jac/dkaf120.
9
Prevalence and molecular characterization of carbapenem-resistant Enterobacterales in patients from a public referral hospital in a non-metropolitan region of Brazil during and post the SARS-CoV-2 pandemic.巴西一个非大都市地区一家公共转诊医院的患者在新冠疫情期间及之后耐碳青霉烯类肠杆菌科细菌的流行情况及分子特征
Braz J Microbiol. 2024 Dec;55(4):3873-3884. doi: 10.1007/s42770-024-01531-7. Epub 2024 Oct 1.
10
Diversity of carbapenemase genes among carbapenem resistant Klebsiella pneumoniae in a tertiary care hospital in Bangkok, Thailand.泰国曼谷一家三级护理医院中耐碳青霉烯类肺炎克雷伯菌的碳青霉烯酶基因多样性
Acta Microbiol Immunol Hung. 2025 Jun 10;72(2):119-126. doi: 10.1556/030.2025.02599. Print 2025 Jun 20.

引用本文的文献

1
Clinical outcomes in patients with cancer and Gram-negative bloodstream infection: impact of carbapenem resistance.癌症患者合并革兰阴性菌血流感染的临床结局:碳青霉烯类耐药性的影响
Support Care Cancer. 2025 Jul 16;33(8):694. doi: 10.1007/s00520-025-09746-6.
2
Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.巴西两家三级医院中与死亡相关的耐碳青霉烯类肠杆菌血流感染
BMC Infect Dis. 2025 May 21;25(1):725. doi: 10.1186/s12879-025-11115-x.
3
Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study.

本文引用的文献

1
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.美国传染病学会2023年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
2
Clinical Characteristics and Associated Factors for Mortality in Patients with Carbapenem-Resistant Bloodstream Infection.耐碳青霉烯类血流感染患者的临床特征及死亡相关因素
Microorganisms. 2023 Apr 25;11(5):1121. doi: 10.3390/microorganisms11051121.
3
Comparison of in vitro fosfomycin susceptibility testing methods with agar dilution for carbapenem resistant Klebsiella pneumoniae and Escherichiacoli.
静脉注射磷霉素的真实世界应用、有效性及安全性:FORTRESS研究
Infect Dis Ther. 2025 Apr;14(4):765-791. doi: 10.1007/s40121-025-01125-2. Epub 2025 Mar 19.
针对耐碳青霉烯类肺炎克雷伯菌和大肠埃希菌,体外磷霉素药敏试验方法与琼脂稀释法的比较
Indian J Med Microbiol. 2023 Mar-Apr;42:39-45. doi: 10.1016/j.ijmmb.2023.01.005. Epub 2023 Feb 2.
4
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).美国医院耐碳青霉烯类肠杆菌科细菌中碳青霉烯酶的流行病学变化以及氨曲南-阿维巴坦对当代肠杆菌科细菌的活性(2019 - 2021年)
Open Forum Infect Dis. 2023 Jan 31;10(2):ofad046. doi: 10.1093/ofid/ofad046. eCollection 2023 Feb.
5
Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand.泰国一家省级医院静脉注射磷霉素的处方模式
Infect Chemother. 2022 Dec;54(4):699-710. doi: 10.3947/ic.2022.0098. Epub 2022 Nov 11.
6
The burden of carbapenem-resistant infection in a large Thai tertiary care hospital.泰国一家大型三级护理医院中耐碳青霉烯类感染的负担。
Front Pharmacol. 2022 Sep 2;13:972900. doi: 10.3389/fphar.2022.972900. eCollection 2022.
7
Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western Thailand.泰国西部多中心分离的耐碳青霉烯类肠杆菌科细菌的抗菌活性谱及潜在抗菌方案
Antibiotics (Basel). 2022 Mar 7;11(3):355. doi: 10.3390/antibiotics11030355.
8
A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.一项在OXA-48流行地区针对耐碳青霉烯类肺炎克雷伯菌血流感染临床流行病学的回顾性观察队列研究。
Int J Antimicrob Agents. 2022 Apr;59(4):106554. doi: 10.1016/j.ijantimicag.2022.106554. Epub 2022 Feb 14.
9
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).欧洲临床微生物学和传染病学会(ESCMID)治疗多重耐药革兰氏阴性杆菌感染的指南(由欧洲重症监护医学学会认可)。
Clin Microbiol Infect. 2022 Apr;28(4):521-547. doi: 10.1016/j.cmi.2021.11.025. Epub 2021 Dec 16.
10
The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Clinical Isolates Harboring Different Carbapenemase Types in a Thai University Hospital.头孢他啶-阿维巴坦对携带不同碳青霉烯酶类型的耐碳青霉烯临床分离株在泰国大学医院的潜在应用。
Drug Des Devel Ther. 2021 Jul 16;15:3095-3104. doi: 10.2147/DDDT.S321147. eCollection 2021.